Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden.
about
JAK2 and genomic instability in the myeloproliferative neoplasms: a case of the chicken or the egg?Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasmsGerm line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasmsRisk factors for vascular complications and treatment patterns at diagnosis of 2389 PV and ET patients: Real-world data from the Swedish MPN Registry.JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms.A multidisciplinary investigation of a polycythemia vera cancer cluster of unknown originDifferential sensitivity to JAK inhibitory drugs by isogenic human erythroblasts and hematopoietic progenitors generated from patient-specific induced pluripotent stem cellsAutoimmunity and the risk of myeloproliferative neoplasms.The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasmsFamilial Essential Thrombocythemia Associated with MPL W515L Mutation in Father and JAK2 V617F Mutation in Daughter.Genetic association between germline JAK2 polymorphisms and myeloproliferative neoplasms in Hong Kong Chinese population: a case-control study.Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasmsThe JAK2 46/1 haplotype (GGCC) in myeloproliferative neoplasms and splanchnic vein thrombosis: a pooled analysis of 26 observational studies.The role of genotypes that modify the toxicity of chemical mutagens in the risk for myeloproliferative neoplasms.Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms.Familial aggregation of acute myeloid leukemia and myelodysplastic syndromesA risk of essential thrombocythemia in carriers of constitutional CHEK2 gene mutationsFamilial aggregation of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia with solid tumors and myeloid malignancies.The Polymorphisms in LNK Gene Correlated to the Clinical Type of Myeloproliferative Neoplasms.Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study.Evaluation of the association between the JAK2 46/1 haplotype and chronic myeloproliferative neoplasms in a Brazilian population.Clinical utility gene card for: familial polycythaemia vera.Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.Elevated risk of chronic lymphocytic leukemia and other indolent non-Hodgkin's lymphomas among relatives of patients with chronic lymphocytic leukemia.Germline and somatic JAK2 mutations and susceptibility to chronic myeloproliferative neoplasms.Gene and microRNA analysis of neutrophils from patients with polycythemia vera and essential thrombocytosis: down-regulation of micro RNA-1 and -133aPatterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in Sweden.Clinical Features of 294 Turkish Patients with Chronic Myeloproliferative Neoplasms.From leeches to personalized medicine: evolving concepts in the management of polycythemia vera.Anthropometric, medical history and lifestyle risk factors for myeloproliferative neoplasms in the Iowa Women's Health Study cohortAdvances in understanding the pathogenesis of familial thrombocythaemia.Environmental, lifestyle, and familial/ethnic factors associated with myeloproliferative neoplasms.Inheritance of the chronic myeloproliferative neoplasms. A systematic review.Genetic and epigenetic alterations of myeloproliferative disorders.Inherited predisposition to myeloproliferative neoplasmsEmerging drugs for polycythemia vera.Back to biology: new insights on inheritance in myeloproliferative disorders.Obesity and related risk of myeloproliferative neoplasms among israeli adolescents.Advances in understanding the pathogenesis of familial myeloproliferative neoplasms.
P2860
Q27012572-F5227D81-0768-4E05-BFE2-D8617B00B7B2Q27687464-7EE0457D-42EC-4E6F-80E6-0776A7BD444CQ27851467-0A12A2CD-2343-465D-A89B-679F07CD66F1Q28392728-FF1C64A9-DFF1-4519-B13F-E50A9A1165C8Q31169518-D53F6C1F-5763-41EA-98B5-F338915CADDBQ33383709-4DF9E4BE-7129-4E74-B663-E9E19D11E385Q33858849-05EF5999-17DD-486B-89D8-F9764DF5A810Q33894805-D4042077-E4E7-42B5-809F-EE28A8F2E549Q33952854-6D26CA8A-5B30-4A97-8C31-8DAA8CE55653Q34612586-C3CAF469-49DE-4065-976D-C20ED6262C53Q34708033-0634FF39-AB86-4D05-97A8-19A15ADA3C66Q34951144-15DBA9CF-E342-49D9-90D1-83BF09239DABQ35023473-30CBB7AF-F464-4B5C-AC3F-CADB69673AFCQ35205659-4FEC40A6-A95F-43B0-A136-700C5098936BQ35227976-6494CB0D-1F49-467B-98E9-FC2A73B2CD1FQ35407362-B10815E1-0586-43BD-B8EB-7E1E9ED7F40DQ35665103-84173534-38FB-47D4-A4EA-EE29F12B5B77Q35794421-F8E34D26-2A34-4F76-B313-51B72E10ED17Q35888716-508739A6-A8DC-4894-8536-4FE0928614C5Q35998214-3BD77C38-DEA4-4142-B897-400AC3A03C1EQ36157668-784DFA23-D027-488F-9694-CDF6A1CD9AC0Q36554959-CFAD3B60-482C-40A1-9851-5221258B3883Q36856469-919E6980-DBE5-4959-97E3-F7E76975F2A3Q37163590-5795B91B-3799-4538-9607-F82DAAE42E0DQ37175576-AF2BCC80-8238-43C5-9CB9-B048EA45A470Q37210008-5DB7A21E-8609-416D-98F8-B40F044BEFE2Q37241550-3C4624D1-5FB9-4994-A740-C11956CBD62CQ37332552-384699AD-8315-4D6A-B948-E0700C4D03BEQ37417438-CD3B352E-38AB-4A4B-91C4-205433173E96Q37555790-57CA6D2E-232D-4D1F-9586-FD0C3DE76440Q37625875-593C9AC3-ABC1-45DE-9A49-FC0FA097752DQ37837958-22048F35-DC8C-47DA-BE75-C2D31B0A7283Q37955142-CDE17BF5-9149-4174-B31A-EC5282E017B2Q38055219-1FB6E019-A11F-45F9-BEAC-7B98A48C4116Q38066786-9A8595FD-979A-4CBD-B3A2-E523C84FBE3CQ38127417-8D1D0E0F-CCA3-483A-B4D7-5939C92B5C69Q38130749-E67508CD-6F37-4426-9FDB-64FB456CFDC1Q38246597-3E836AF8-6687-42DF-BB73-339B89D7D814Q38684403-6C650C4F-326F-4F7F-9913-5E203EDDF458Q39263948-5C95A587-3E2C-47DF-9AB5-33F2A4FC4043
P2860
Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Increased risks of polycythemi ...... iferative neoplasms in Sweden.
@en
type
label
Increased risks of polycythemi ...... iferative neoplasms in Sweden.
@en
prefLabel
Increased risks of polycythemi ...... iferative neoplasms in Sweden.
@en
P2093
P2860
P1433
P1476
Increased risks of polycythemi ...... iferative neoplasms in Sweden.
@en
P2093
Elin A Helgadottir
Jan Samuelsson
Lynn R Goldin
Magnus Björkholm
Sigurdur Y Kristinsson
P2860
P304
P356
10.1182/BLOOD-2008-03-143602
P407
P50
P577
2008-05-01T00:00:00Z